Risk of immunomediated adverse events and loss of response to infliximab in elderly patients with inflammatory bowel disease. A cohort study of the ENEIDA registry.
Margalida CalafatMíriam MañosaElena RicartPilar NosEva Iglesias-FloresIsabel VeraAntonio López-SanRománJordi GuardiolaCarlos TaxoneraMiguel MínguezM Dolores Martín-ArranzLuisa de CastroRuth de FranciscoMontserrat RiveroEsther Garcia-PlanellaXavier CalvetSantiago García-LópezLucía MárquezFernando GomollónJesús BarrioMaría EsteveFernándo MuñozJavier P GisbertAna GutiérrezJoaquín HinojosaFederico Argüelles-AriasDavid BusquetsLuís BujandaJosé L Pérez-CalleBeatriz SiciliaOlga MerinoPilar MartínezFernando BermejoRufo LorenteManuel Barreiro-de AcostaCristina RodríguezMariana Fe García-SepulcreDavid MonfortFiorella CañeteEugeni Domènechnull nullPublished in: Journal of Crohn's & colitis (2021)
Elderly patients with IBD have a similar risk of developing infliximab-related IAEs and LOR to that of younger patients.